Farletuzumab-MMAE (ADC)

Catalog No.

DHD10497

Description

Farletuzumab-MMAE is an ADC consisting of an FRA-directed antibody and Monomethyl auristatin E (MMAE) used for the study of non-small cell lung cancer.

Species reactivity

Human

Clonality

Monoclonal

Target

FRA

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>90% as determined by SEC.

Purification

Purified by Ion Exchange Chromatography.

Applications

Research Grade Biosimilar

Form

Liquid

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

Farletuzumab-MMAE

Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer models., PMID:40074693

Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors., PMID:39853764

Efficacy and Safety of Farletuzumab in Ovarian Cancer: A Systematic Review and Single-Arm Meta-Analysis., PMID:39677200

The Efficacy and Safety of Folate Receptor α-Targeted Antibody-Drug Conjugate Therapy in Patients With High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers: A Systematic Review and Meta-Analysis., PMID:39526448

Integrating antibody drug conjugates in the management of gynecologic cancers., PMID:36878560

Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer., PMID:36758420

Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer., PMID:34185411

First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors., PMID:33926914

Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models., PMID:33756060

Evaluation of therapeutic efficacy of 211At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer., PMID:32987283

Exploiting the folate receptor α in oncology., PMID:32152484

Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast., PMID:30268765

MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity., PMID:30262588

Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding., PMID:30144039

Farletuzumab, a monoclonal antibody directed against folate receptor alpha, shows no evidence of teratogenicity in cynomolgus monkeys., PMID:29928988

FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125., PMID:29041009

CA125 effects on humoral immunosuppression., PMID:29016358

Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement., PMID:28881712

Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging., PMID:28826214

Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer., PMID:28450240

Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer., PMID:27797594

Profile of farletuzumab and its potential in the treatment of solid tumors., PMID:27022278

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse., PMID:27001568

Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer., PMID:26644263

Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors., PMID:26136852

Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments., PMID:26063635

Folate receptor-α (FOLR1) expression and function in triple negative tumors., PMID:25816016

Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives., PMID:25765457

Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications., PMID:25564455

Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer., PMID:25416196

A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors., PMID:25380636

Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy., PMID:25363562

Major clinical research advances in gynecologic cancer in 2013., PMID:25045437

Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review., PMID:25031539

Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging., PMID:24732155

International Association for the Study of Lung Cancer - 15th World Conference on Lung Cancer (October 27-31, 2013 - Sydney, Australia)., PMID:24524099

Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer., PMID:24109193

The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity., PMID:24025360

Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer., PMID:23863359

Antibodies to watch in 2013: Mid-year update., PMID:23727858

Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer., PMID:23474348

Farletuzumab in lung cancer., PMID:23357463

Which are the antibodies to watch in 2013?, PMID:23254906

Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer., PMID:22955257

Clinical trials and future potential of targeted therapy for ovarian cancer., PMID:22926640

Clinical translation of folate receptor-targeted therapeutics., PMID:22663189

Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro., PMID:22644798

Role of farletuzumab in epithelial ovarian carcinoma., PMID:22591419

Molecular/genetic therapies in ovarian cancer: future opportunities and challenges., PMID:22343235

Monoclonal antibodies in gynecological cancer: a critical point of view., PMID:22235224

Document Download

Farletuzumab-MMAE (ADC).pdf